Cargando…

The Pharmacological Potential of Adenosine A(2A) Receptor Antagonists for Treating Parkinson’s Disease

The adenosine A(2A) receptor subtype is recognized as a non-dopaminergic pharmacological target for the treatment of neurodegenerative disorders, notably Parkinson’s disease (PD). The selective A(2A) receptor antagonist istradefylline is approved in the US and Japan as an adjunctive treatment to lev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Akihisa, Chen, Jiang-Fan, Uchida, Shinichi, Durlach, Cecile, King, Shelby M., Jenner, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000505/ https://www.ncbi.nlm.nih.gov/pubmed/35408767 http://dx.doi.org/10.3390/molecules27072366

Ejemplares similares

How Are Adenosine and Adenosine A(2A) Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis?
por: Mori, Akihisa, et al.
Publicado: (2021)

Pharmacological characterisation of novel adenosine A(3) receptor antagonists
por: Barkan, Kerry, et al.
Publicado: (2020)

Novel selective antagonist radioligands for the pharmacological study of A(2B) adenosine receptors
por: Gessi, Stefania, et al.
Publicado: (2006)

Effects of Adenosine Receptor Antagonists on the In Vivo LPS-Induced Inflammation Model of Parkinson’s Disease
por: Gołembiowska, Krystyna, et al.
Publicado: (2013)

Do caffeine and more selective adenosine A(2A) receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease?
por: Chen, Jiang-Fan, et al.
Publicado: (2020)

Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity
por: Essawy, Soha S., et al.
Publicado: (2017)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches
por: Nazario, Luiza R., et al.
Publicado: (2017)

Pharmacology of Adenosine Receptors: Recent Advancements
por: Vincenzi, Fabrizio, et al.
Publicado: (2023)

Adenosine A(2A) receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease
por: Mizuno, Yoshikuni, et al.
Publicado: (2013)

Irreversible Antagonists for the Adenosine A(2B) Receptor †
por: Temirak, Ahmed, et al.
Publicado: (2022)

Effect of Adenosine Receptor Antagonists on Adenosine-Pretreated PC12 Cells Exposed to Paraquat
por: Shang, Liangcheng, et al.
Publicado: (2022)

Untargeted Metabolomics Reveals the Potential Antidepressant Activity of a Novel Adenosine Receptor Antagonist
por: Smith, Arnold Petrus, et al.
Publicado: (2022)

Effects of GABAa receptor antagonists on motor behavior in pharmacological Parkinson's disease model in mice
por: Mograbi, Karla De Michelis, et al.
Publicado: (2017)

Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
por: Vincenzi, Fabrizio, et al.
Publicado: (2020)

Fluorinated Adenosine A(2A) Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics
por: Yuan, Gengyang, et al.
Publicado: (2017)

Adenosine A(2A) Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges
por: Franco, Rafael, et al.
Publicado: (2018)

Treatment of the later stages of Parkinson’s disease – pharmacological approaches now and in the future
por: Jenner, Peter
Publicado: (2015)

A covalent antagonist for the human adenosine A(2A) receptor
por: Yang, Xue, et al.
Publicado: (2016)

Tumor Immunotherapy Using A(2A) Adenosine Receptor Antagonists
por: Zhang, Jinfeng, et al.
Publicado: (2020)

A(3) Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity
por: Spinaci, Andrea, et al.
Publicado: (2022)

Potential Treat-to-Target Approach for Methamphetamine Use Disorder: A Pilot Study of Adenosine 2A Receptor Antagonist With Positron Emission Tomography
por: Okita, Kyoji, et al.
Publicado: (2022)

Development of a Radiofluorinated Adenosine A(2B) Receptor Antagonist as Potential Ligand for PET Imaging
por: Lindemann, Marcel, et al.
Publicado: (2020)

Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
por: Yang, Zijian, et al.
Publicado: (2015)

Adenosine A(2A) receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
por: Zhou, Rong, et al.
Publicado: (2018)

Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists
por: Tosh, Dilip K., et al.
Publicado: (2018)

Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes
por: Bolcato, Chiara, et al.
Publicado: (2007)

Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients
por: Kitta, Takeya, et al.
Publicado: (2018)

Pharmacology of the Adenosine A(3) Receptor in the Vasculature and Essential Hypertension
por: Ho, Ming-Fen, et al.
Publicado: (2016)

Species dependence of A(3) adenosine receptor pharmacology and function
por: Gao, Zhan-Guo, et al.
Publicado: (2022)

Arbutin effectively ameliorates the symptoms of Parkinson’s disease: the role of adenosine receptors and cyclic adenosine monophosphate
por: Zhao, Jie, et al.
Publicado: (2021)

A(2B) adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models
por: Tay, Apple Hui Min, et al.
Publicado: (2022)

Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2015)

Identification of Novel Adenosine A(2A) Receptor Antagonists by Virtual Screening
por: Langmead, Christopher J., et al.
Publicado: (2012)

Striatal Pre- and Postsynaptic Profile of Adenosine A(2A) Receptor Antagonists
por: Orru, Marco, et al.
Publicado: (2011)

The seeming paradox of adenosine receptors as targets for the treatment of Alzheimer's disease: agonists or antagonists?
por: Marzagalli, Rubina, et al.
Publicado: (2015)

Pyrazolo Derivatives as Potent Adenosine Receptor Antagonists: An Overview on the Structure-Activity Relationships
por: Cheong, Siew Lee, et al.
Publicado: (2011)

The Adenosine Receptor Antagonist, 7-Methylxanthine, Alters Emmetropizing Responses in Infant Macaques
por: Hung, Li-Fang, et al.
Publicado: (2018)

Free-Energy Calculations for Bioisosteric Modifications of A(3) Adenosine Receptor Antagonists
por: Jandova, Zuzana, et al.
Publicado: (2019)

Computational studies of the binding modes of A(2A) adenosine receptor antagonists
por: Ye, Y., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_fsfqto4r0a0mlq129hs8k1r33v